What does CUSIP 82835W108 represent in this 13F holders report?

CUSIP 82835W108 is the security identifier for SPRY - ARS Pharmaceuticals, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held SPRY - ARS Pharmaceuticals, Inc. - Common Stock in Q4 2022?

72 institutional investors reported SPRY - ARS Pharmaceuticals, Inc. - Common Stock for Q4 2022. Use the holders table for investor-level position and value details.

ARS Pharmaceuticals, Inc. - Common Stock (SPRY)

CUSIP: 82835W108

Q4 2022 13F Holders as of 31 Dec 2022

Security type / class: Equity / Common Stock
Total 13F shares: 50,164,476
Total 13F value: $427,856,540
Share change: +19,674,795
Put/Call ratio: 0%
SEC-reported price per share: $8.53
Number of holders: 72
Value change: +$173,112,031
Number of buys: 46
Number of sells: 24
Shares outstanding: 98,457,811

Security key

82835W108

Report period

Q4 2022

Institutions

Top holders

SPRY full security history Ownership snapshot Full 13F holder table ARS Pharmaceuticals, Inc. SEC filings ARS Pharmaceuticals, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of SPRY - ARS Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

ORBIMED ADVISORS LLC

Disclosed value leader

ORBIMED ADVISORS LLC

Comparable rows

15/15

Latest evidence

30 Sep 2022

13F Lead comparable stake: 8.9% Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 8.9%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.

Comparable ownership Top 5

ORBIMED ADVISORS LLC 8.9%

FMR LLC 4.8%

K2 PRINCIPAL FUND, L.P. 3.3%

Rubric Capital Management LP 2.7%

Nextech Invest Ltd. 1.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
ORBIMED ADVISORS LLC	13F Company 13F	8.9%	$46,152,000 8,740,887 shares	—	30 Sep 2022
FMR LLC	13F Company 13F	4.8%	$25,152,000 4,763,501 shares	—	30 Sep 2022
K2 PRINCIPAL FUND, L.P.	13F Company 13F	3.3%	$16,890,000 3,247,533 shares	—	30 Sep 2022
Rubric Capital Management LP	13F Company 13F	2.7%	$14,230,000 2,695,170 shares	—	30 Sep 2022
Nextech Invest Ltd.	13F Company 13F	1.9%	$10,085,000 1,910,029 shares	—	30 Sep 2022
Nantahala Capital Management, LLC	13F Company 13F	1.3%	$6,599,000 1,249,863 shares	—	30 Sep 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

50,164,476

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders

Q4 2022 holders

Holder diff

Investor	Q3 2022 Shares	Q4 2022 Shares	Share Diff	Share Chg %	Q3 2022 value	Q4 2022 value	Value change	Value Chg %